Introduction
============

Carcinoma of the ampulla of Vater is the most common cancer of the small intestine and is commonly adenocarcinoma ([@b1-or-36-04-1997]). The ampulla of Vater is located in the second portion of the duodenum, at the confluence of the common bile and pancreatic duct. Long-term exposure to bile acids is a possible reason for malignant transformation. Bile acids are potential carcinogens in gastrointestinal cancer, including gastric, esophageal and colon cancer, and cholangiocarcinoma ([@b2-or-36-04-1997]). Incidences of intestinal metaplasia and gastric cardia cancer are increased in patients with gastroesophageal reflux disease ([@b3-or-36-04-1997]). Treatment of squamous cell carcinoma cell lines of the esophagus with bile acids induces cell cycle progression and production of G1-regulating molecules ([@b4-or-36-04-1997]). The secondary bile acids, deoxycholate and lithocholate, are the most well-known carcinogens in human colon cancer and are associated with the generation of reactive oxygen/nitrogen species (ROS/RNS) ([@b5-or-36-04-1997]). The accumulation of ROS/RNS was found to cause oxidative DNA damage and further mutation in colon cancer ([@b6-or-36-04-1997]). The conjugated bile acid glycochenodeoxycholate (GCDA) induced expression of cyclooxygenase 2 (COX-2) and genes that are related to cell proliferation in cholangiocytes ([@b7-or-36-04-1997]). Another type of conjugated bile acid, taurochenodeoxycholate (TCDA), induced phosphorylation of epidermal growth factor receptor (EGFR) and its downstream signaling in a human cholangiocarcinoma cell line ([@b8-or-36-04-1997]).

Bile acids interact with several types of nuclear receptors, including farnesoid X receptor (FXR), vitamin D receptor, pregnane X receptor, and constitutive androstane receptor ([@b9-or-36-04-1997]). Nuclear receptors are ligand-modulated transcription factors and regulate uptake, detoxification and secretion of bile acids. FXR is the main form of nuclear receptor of bile acids expressed in the gastrointestinal tract where it mediates homeostasis of bile acids, lipids and glucose. Expression of FXR is reduced in human colon cancer or Barrett\'s esophageal cancer. FXR functions as a tumor suppressor in colon, liver and esophageal cancer ([@b10-or-36-04-1997]--[@b12-or-36-04-1997]). The oncosuppressive roles of FXR in these cancers include suppression of proliferation and induction of apoptosis after exposure to bile acids. Bile acids also act as systemic hormones when interacting with membrane receptors, such as G protein-coupled bile acid receptor 1 (gene *GPBAR1*; also known as TGR5, M-BAR and BG37). Bile acid-dependent TGR5 activation is involved in the immunomodulatory properties of bile acids, synthesis of endothelial nitric oxide, and mitochondrial energy homeostasis ([@b2-or-36-04-1997],[@b9-or-36-04-1997]). In the normal physiologic condition, the functions of TGR5 include modulation of gallbladder filling, improvement of insulin sensitivity, maintenance of glucose homeostasis, and increased energy expenditure to attenuate diet-induced obesity ([@b13-or-36-04-1997],[@b14-or-36-04-1997]). The function of TGR5 is variable in different types of cancer ([@b15-or-36-04-1997]). Expression of TGR5 is increased in the intestinal subtype of gastric adenocarcinoma and intestinal metaplasia, but not in normal gastric epithelium. Mild to strong TGR5 staining is associated with poor patient survival, and TCDA increased proliferation of a gastric adenocarcinoma cell line through the TGR5-dependent pathway ([@b16-or-36-04-1997]). TDCA-induced ROS production and cell proliferation are mediated through TGR5 in Barrett\'s esophageal and esophageal adenocarcinoma cell lines ([@b17-or-36-04-1997]). Stimulation with bile acids prompted the proliferation of an endometrial cell line by activating TGR5 and inducing cyclin D1 expression ([@b18-or-36-04-1997]). In contrast to patients with gastric, esophageal and endometrial cancer, the binding of bile acids to TGR5 induced c-Jun-N terminal kinase (JNK) activation and enhanced apoptosis in hepatocytes ([@b19-or-36-04-1997]). TGR5-deficient mice are much more susceptible to chemically induced acute liver injury with increased incidence of liver cancer ([@b20-or-36-04-1997]). TGR5 may promote or suppress carcinogenesis after stimulation by bile acids ([@b2-or-36-04-1997]). Since the role of bile acids in ampullary cancer is largely unknown, in the present study, we investigated the role of TGR5 in ampullary adenocarcinoma.

Materials and methods
=====================

Bioinformatic analysis
----------------------

First, we conducted a search of the Kaplan-Meier plotter database (<http://kmplot.com/analysis/>) to systematically assess the expression level of the *GPBAR1* gene in gastric, breast, lung and ovarian cancer patients ([@b21-or-36-04-1997]--[@b23-or-36-04-1997]). Kaplan-Meier Plot survival curves were drawn. Second, a PrognoScan database (<http://www.abren.net/PrognoScan/>) analysis was conducted. The expression level of the *GPBAR1* gene was correlated with the survival of cancer patients. Third, data of *GPBAR1* gene expression from genomics studies of 30 types of human cancer in the cBioPortal database (<http://www.cbioportal.org/index.do>) were examined ([@b24-or-36-04-1997],[@b25-or-36-04-1997]). Mutation of the *GPBAR1* gene was documented by oncogenomic analysis.

Patients
--------

A total of 99 patients who were diagnosed as having ampullary adenocarcinoma and who underwent radical resection at National Cheng Kung University Hospital from January 1990 to January 2010 were enrolled. Patients who received conservative treatment or exhibited other cell types of ampullary cancer were excluded. Demographics, histopathological findings and clinical outcomes were collected by conducting a retrospective chart review. A formal written informed consent was obtained from each patient. Their medical charts were reviewed until January 2016. The disease-specific survival rate was defined as the period from surgery until cancer-related death. The present study was approved by the Institutional Review Board of the National Cheng Kung University Hospital (NCKUH IRB no. A-ER-101-390 and B-ER-103-408).

Western blotting
----------------

Total protein lysates from tumor specimens and corresponding specimens of normal duodenum were obtained from the same patient and the protein concentration of the supernatants was measured using the amido black method. Equivalent amounts of protein (30 *µ*g) were separated on 10--15% polyacrylamide gels by SDS-gel electrophoresis, transferred to polyvinylidene difluoride membranes, and probed with the antibody against TGR5 (Abcam Biotechnology, Cambridge, UK), FXR (R&D, Abingdon, UK), and GAPDH (Cell Signaling Technology, Danvers, MA, USA) proteins. Protein expression was visualized by ECL chemiluminescence (Promega, Madison, WI, USA) and quantitated by comparison with GAPDH.

Semi-quantitative reverse transcription polymerase chain reaction (RT-PCR)
--------------------------------------------------------------------------

The fresh cancer tissues and normal duodenum from the same patient, were obtained for RT-PCR. The total RNA was extracted from fresh tissues, and single-stranded cDNA was synthesized using oligo(dT) as the random primer. The cDNA was amplified using the primers for β-actin, *GPBAR1* and *FXR* genes, which were: β-actin sense, 5′-AGCGGGAAATCGTGCGTG-3′; and β-actin antisense, 5′-CAGGGTACATGGTGGTGGTGCC-3′; *GPBAR1* sense, 5′-CCCAGGCTATCTTCCCAGC-3′ and *GPBAR1* antisense, 5′-GCCAGGACTGAGAGGAGCA-3′; *FXR* sense, 5′-GACTTTGGACCATGAAGACCAG-3′ and *FXR* antisense, 5′-GCCCAGACGGAAGTTTCTTATT-3′. The RT-PCR products were analyzed using agarose gel electrophoresis, and the GPBAR1 or FXR bands were semi-quantified using densitometric analysis and subsequently normalized relative to the β-actin bands.

Immunohistochemical (IHC) staining
----------------------------------

Samples of ampullary adenocarcinoma and the surrounding duodenum were fixed in 4% formalin and embedded in paraffin. IHC staining was performed using a monoclonal mouse anti-human TGR5 antibody (Abcam Biotechnology). The sections were incubated using an avidin-biotin complex reagent (Dako, Carpinteria, CA, USA), incubated with 3-amino-9-ethyl carbazole (Zymed Laboratories, South San Francisco, CA, USA) to develop the final color, and counterstained with hematoxylin. The immunoreactivity of the TGR5 protein was assessed using a semi-quantitative method and according to the Remmele and Stegner immunoreactive scoring (IRS) system ([@b26-or-36-04-1997]). The IRS scores ranged from 0 to 12 and immunoreactivity was characterized as negative, weak, mild and strong. One researcher assessed the lesions (H.P. Hsu).

Statistical analysis
--------------------

All statistical analyses were conducted using SPSS version 12.0 (SPSS, Inc., New York, NY, USA). A univariate analysis of the categorical variables was performed using the Chi-square test. The continuous variables were compared using the non-parametric Kruskal-Wallis H test. Any association between specific markers and the recurrence-free survival of patients was assessed using the Kaplan-Meier method, and the level of significance was tested using the log-rank test. A P-value of \<0.05 was considered to indicate a statistically significant result.

Results
=======

Analysis of microarray GAPBR1 gene expression data
--------------------------------------------------

Several gene expression databases of human cancer genetics are available at websites, including the Kaplan-Meier plotter, PrognoScan and cBioPortal system. There is no public database of ampullary adenocarcinoma genetics. Other human cancer types were used to study the function of TGR5 (gene name: *GPBAR1*). These three databases were used to assess *GPBAR1* gene expression and correlate it with clinical outcome. Analysis of the relationship of the *GPBAR1* gene expression level (based on Kaplan-Meier plotter data) to survival in patients with gastric, breast, lung and ovarian cancer ([Fig. 1](#f1-or-36-04-1997){ref-type="fig"}) revealed that prognosis was poorer in gastric cancer and breast cancer patients with high *GPBAR1* gene expression than in those with low expression ([Fig. 1A and B](#f1-or-36-04-1997){ref-type="fig"}). *GPBAR1* gene expression was not correlated with overall survival of patients with lung cancer ([Fig. 1C](#f1-or-36-04-1997){ref-type="fig"}). Ovarian cancer patients with high *GPBAR1* gene expression tended to have a better prognosis than those with low expression ([Fig. 1D](#f1-or-36-04-1997){ref-type="fig"}). The function of *GPBAR1* gene in tumor development differed between these four types of cancer.

Prognoscan is a collection of human cancer microarray data-sets
---------------------------------------------------------------

High *GPBAR1* gene expression predicted a trend toward poor prognosis in 12 datasets ([Table I](#tI-or-36-04-1997){ref-type="table"}) and good prognosis in 15 datasets ([Table II](#tII-or-36-04-1997){ref-type="table"}). In most datasets, the *GPBAR1* gene expression was not significantly correlated with survival and only one dataset in each group displayed predictive power (GSE13507 and GSE8894). The level of *GPBAR1* expression in human cancer was investigated using the cBioPortal system and analyzed in 30 types of cancer ([Fig. 2A](#f2-or-36-04-1997){ref-type="fig"}). Three specific types of cancer (cholangiocarcinoma, pancreatic and colorectal cancer) were compared ([Fig. 2B](#f2-or-36-04-1997){ref-type="fig"}). Cholangiocarcinoma and pancreatic cancer are continuously exposed to bile and toxic bile acids are well-established carcinogens for cholangiocarcinoma and colorectal cancer. Cholangiocarcinoma and pancreatic cancer, compared to other cancers, had a higher level of *GPBAR1* expression ([Fig. 2B](#f2-or-36-04-1997){ref-type="fig"}). Thus the function of *GPBAR1* is distinct in different cancers, and its expression may be correlated with bile exposure.

Expression of TGR5 protein in ampullary cancer
----------------------------------------------

The ampulla of Vater is located in the second part of the duodenum and is exposed to bile acids under normal physiological conditions. TGR5 protein (product of the *GPBAR1* gene) and *GPBAR1* mRNA were detected in clinical samples of ampullary cancer and the surrounding normal duodenum ([Fig. 3](#f3-or-36-04-1997){ref-type="fig"}). In the patients with cancer recurrence, the TGR5 protein level was lower in the tumor than that noted in the normal duodenum. In the patients without cancer recurrence, the tumor TGR5 level was similar to the normal tissue level. In contrast, no such pattern was found for FXR protein ([Fig. 3A](#f3-or-36-04-1997){ref-type="fig"}). Increased *GPBAR1* mRNA was detected in 7 of 15 specimens of ampullary cancer, particularly in well-differentiated ampullary adenocarcinoma ([Fig. 3B and C](#f3-or-36-04-1997){ref-type="fig"}). Expression of FXR mRNA was not correlated with histological differentiation ([Fig. 3C](#f3-or-36-04-1997){ref-type="fig"}).

Immunohistochemical staining of TGR5 in ampullary cancer
--------------------------------------------------------

To study the relationship of TGR5 protein expression with clinical outcome, 99 specimens of ampullary adenocarcinoma were immunostained for TGR5. TGR5 was detected in the cytoplasm and nucleus of each cancer cell ([Fig. 4](#f4-or-36-04-1997){ref-type="fig"}). We divided the result as negative, weak, mild and strong expression of TGR5. Expression of TGR5 was negative in 14 patients, weak in 33, mild in 29, and strong in 23 ([Table I](#tI-or-36-04-1997){ref-type="table"}). Negative, weak or mild expression of TGR5 was correlated with younger age (P=0.043) and higher level of direct bilirubin (P=0.023, separately) and tended to be correlated with higher level of total bilirubin (P=0.059), higher plasma level of cancer antigen-125 (CA-125) (P=0.099), advanced tumor stage and AJCC TNM stage (P=0.063 and 0.062, separately) ([Table III](#tIII-or-36-04-1997){ref-type="table"}).

Correlation of TGR5 expression with clinical outcomes of ampullary cancer patients
----------------------------------------------------------------------------------

In 95 patients with regular follow-up (range, 3--249 months), 55 patients developed recurrence. The recurrences in patients with negative, weak or mild TGR5 expression tended to be earlier (within postoperative 12 months) (P=0.089), although the level of TGR5 expression was not associated with recurrence patterns ([Table IV](#tIV-or-36-04-1997){ref-type="table"}). The disease-specific survival rate tended to be better in patients with strong TGR5 expression (P=0.1118; [Fig. 5A](#f5-or-36-04-1997){ref-type="fig"}).

In the literature, the function of TGR5 depends on dysregulation of bile acid homeostasis ([@b2-or-36-04-1997]). We hypothesized that high levels of preoperative bilirubin interacts with TGR5 in ampullary cancer. We grouped the patients according to the median level of total bilirubin (2.45 mg/dl). Although not correlated with survival in the patients with total bilirubin ≤2.45 mg/dl ([Fig. 5B](#f5-or-36-04-1997){ref-type="fig"}), TGR5 expression predicted a better prognosis in patients with higher than 2.45 mg/dl (P=0.0464; [Fig. 5C](#f5-or-36-04-1997){ref-type="fig"}).

Discussion
==========

The ampullary of Vater is normally exposed to bile. This is the first study to investigate expression of the membrane bile acid receptor, TGR5, in ampullary adenocarcinoma. The results of analysis of *GPBAR1* gene expression data (gene of TGR5) in microarray databases was correlated with clinical outcomes and varied between types of cancers. The pathological function of TGR5 in cancer is regulated by a complex mechanism. In ampullary adenocarcinoma, the present study detected TGR5 protein and *GPBAR1* mRNA in the tumor and surrounding normal duodenum. Negative, weak or mild TGR5 expression was correlated with elevation of plasma bilirubin. In the patients with plasma total bilirubin higher than the median, strong TGR5 expression predicted a better prognosis.

There are two types of ampullary adenocarcinoma: intestinal and pancreaticobiliary types. These differ in clinical behavior ([@b27-or-36-04-1997]) and the differences may be intrinsic. Nuclear accumulation of β-catenin promotes WNT activation and cancer progression; however, loss of the β-catenin protein in ampullary cancer is correlated with poor prognosis ([@b28-or-36-04-1997]). Nestin, a stemness protein, performs a dual role in ampullary adenocarcinoma, as a predictor of good prognosis in early cancer and as a promoter of metastasis in advanced cancer ([@b29-or-36-04-1997]). The epithelial cell marker, EpCAM, is one of the signatures of cancer stem cells with oncogenic potential mediated via upregulation of c-myc and cyclins. However, loss of EpCAM is linked to a more aggressive phenotype of ampullary cancer, suggesting that EpCAM may play a different role in ampullary cancer than in other cancers ([@b30-or-36-04-1997]). Ampullary adenocarcinoma is a unique cancer with a 5-year survival rate \<50% after curative resection ([@b27-or-36-04-1997],[@b31-or-36-04-1997],[@b32-or-36-04-1997]). Further study of ampullary adenocarcinoma is required to develop new treatment modalities and improve clinical outcomes.

The ampullary of Vater is located at the confluence of the common bile and pancreatic ducts, and second portion of the duodenum. Long-term exposure to bile acids increases oxidative stress, generates ROS/RNS, and induces cell damage and mutation rates in gastrointestinal cancer ([@b2-or-36-04-1997],[@b5-or-36-04-1997],[@b6-or-36-04-1997]). Alteration of the bile contents of gastroesophageal reflux is correlated with the increased incidence of cancer in cell culture, animal models and epidemiology studies ([@b3-or-36-04-1997],[@b4-or-36-04-1997],[@b33-or-36-04-1997]). Toxic bile acids induce expression of COX-2 or activation of EGFR and promote carcinogenesis in cholangiocarcinoma ([@b7-or-36-04-1997],[@b8-or-36-04-1997]). In our previous study, preoperative plasma concentration of total bilirubin was elevated in non-survivors of ampullary cancer ([@b32-or-36-04-1997]). However, no relationship was found between hyperbilirubinemia and ampullary cancer recurrence.

Bile acids interact not only with nuclear receptors, but also with membrane receptors. TGR5 is a G protein-coupled bile acid receptor that mediates bile acid-regulated energy and glucose homeostasis ([@b2-or-36-04-1997],[@b9-or-36-04-1997],[@b34-or-36-04-1997]). Bile acids induce cell proliferation and cell cycle progression through the TGR5-dependent pathway and TGR5 acts such as an oncoprotein ([@b16-or-36-04-1997]--[@b18-or-36-04-1997]). In hepatocytes, suppression of TGR5 enhances chemical-induced carcinogenesis and activation of TGR5 promotes cell apoptosis ([@b19-or-36-04-1997],[@b20-or-36-04-1997]). Whether TGR5 promotes or suppresses carcinogenesis depends on the composition of the bile acids ([@b2-or-36-04-1997]). We analyzed multiple microarray datasets and found that high *GPBAR1* gene expression predicted poor prognosis in some datasets, but good prognosis in others ([Tables I](#tI-or-36-04-1997){ref-type="table"} and [II](#tII-or-36-04-1997){ref-type="table"}; [Fig. 1](#f1-or-36-04-1997){ref-type="fig"}). Bile acid-exposed cancers (such as cholangiocarcinoma and pancreatic cancer) had a higher ratio of *GPBAR1* expression ([Fig. 2B](#f2-or-36-04-1997){ref-type="fig"}). Since the ampulla of Vater is also exposed to bile acids under normal physiological conditions, the study of bile acid receptors, such as TGR5 and FXR, is indicated in ampullary cancer. In the present study, the mRNAs or proteins of TGR5 or FXR were detected in specimens of ampullary adenocarcinoma ([Fig. 3](#f3-or-36-04-1997){ref-type="fig"}). Increased expression of *GPBAR1* mRNA but not FXR mRNA was correlated with histological differentiation and well-differentiated adenocarcinoma ([Fig. 3C](#f3-or-36-04-1997){ref-type="fig"}). Taken together, our results indicate that the membrane receptor of bile acids, TGR5, may be activated in ampullary cancer.

Activation of TGR5 plays a role in cyclic adenosine monophosphate (cAMP), EGFR, mitogen-activated protein kinase (MAPK, such as JNK, ERK-1/2), cyclooxygenase-2 (COX-2) or signal transducer and activator of transcription 3 (STAT3) signaling ([@b35-or-36-04-1997]). TGR5 functions in a cell type-dependent and context-dependent manner in cancer. In gastric and esophageal cancer, the TGR5-dependent pathway mediates bile acid-induced ROS production and cell proliferation as well as deoxycholate-induced EGFR phosphorylation and ERK1/2 activation. Moreover, TGR5 expression is associated with the poor prognosis of patients ([@b36-or-36-04-1997]--[@b38-or-36-04-1997]), suppresses STAT3 signaling and inhibits cell cycle progression, angiogenesis, metastasis and evasion of the immune system in gastric cancer ([@b36-or-36-04-1997]). Interaction of TGR5 and EGFR depends on lipid rafts. Deoxycholate induces EGFR phosphorylation and ERK1/2 activation through the TGR5-dependent pathway ([@b38-or-36-04-1997]). However, TGR5 performs as a tumor-suppressor in liver cancer. TGR5-deficient mice have an increased incidence of liver cancer ([@b19-or-36-04-1997]). Bile acids conjugate TGR5 to induce JNK activation and enhance apoptosis in hepatocytes ([@b20-or-36-04-1997]). In the present study, strong TGR5 expression was correlated with lower plasma concentration of total and direct bilirubin. The patients with strong TGR5 expression tended to have a lower plasma level of CA-125, earlier tumor stage, and earlier AJCC TNM stage and also a better disease-specific survival rate, particularly those patients with total bilirubin concentration higher than 2.45 mg/dl. We conclude that TGR5 performs as a tumor suppressor in hyperbilirubinemic patients with ampullary adenocarcinoma.

In summary, high TGR5 expression was correlated with lower plasma concentration of total/direct bilirubin, lower plasma level of CA-125, early tumor stage and AJCC TNM stage. High TGR5 expression also predicted a good survival in patients with total bilirubin levelss higher than 2.45 mg/dl. TGR5 performs as a tumor suppressor in hyperbilirubinemia condition of ampullary adenocarcinoma patients.
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![Kaplan-Meier survival analysis of *GPBAR1* gene expression in cancer patients. The data were obtained from the Kaplan-Meier plotter database (<http://kmplot.com/analysis/>). High-*GPBAR1* gene expression is indicated by the red line and low expression by the black line. (A) Overall survival of patients with gastric cancer. (B) Recurrence-free survival of patients with breast cancer. (C) Overall survival of patients with lung cancer. (D) Progression-free survival of patients with ovarian cancer. OS, overall survival; RFS, relapse-free survival; PFS, progression-free survival.](OR-36-04-1997-g00){#f1-or-36-04-1997}

![Analysis of *GPBAR1* expression level data from the cBioPortal database (<http://www.cbioportal.org/index.do>). Every spot represents a single study. White spots represent those analyzed without gene sequencing, blue spots represent normal results of gene sequencing and red spots represent missense mutations. (A) Level of *GPBAR1* expression in 30 types of human cancer. (B) Level of *GPBAR1* expression in three specific-types of cancer (bile acid-exposed cholangiocarcinoma and pancreatic cancer vs. colorectal cancer). The median and interquartile range are presented. The median level of *GPBAR1* gene expression was higher in cholangiocarcinoma and pancreatic cancer than in colorectal cancer.](OR-36-04-1997-g01){#f2-or-36-04-1997}

![Expression of TGR5 and FXR in ampullary adenocarcinoma. Sample pairs consisting of ampullary adenocarcinoma (T) and its corresponding normal duodenum (N) were collected. (A) Eight sample pairs were assessed by western blotting of TGR5 and FXR proteins with GAPDH serving as a loading control. The fold-change of TGR5/GAPDH or FXR/GAPDH is indicated below the band. (B) A total of 15 sample pairs were assessed by semi-quantitative RT-PCR, with β-actin serving as a loading control. The fold-change of TGR5/β-actin or FXR/β-actin is indicated below the band. (C) The proportion of TGR5/β-actin or FXR/β-actin expressed in tumors relative to normal control tissues was correlated with histological differentiation.](OR-36-04-1997-g02){#f3-or-36-04-1997}

![Expression of TGR5 in ampullary adenocarcinoma was assessed by immunohistochemical (IHC) staining and rated using the Remmele and Stegne immunoreactive scoring system. Expression was either (A) 0--1 (negative); (B) 2--3 (weak); (C) 4--8 (mild) or (D) 9--12 (strong).](OR-36-04-1997-g03){#f4-or-36-04-1997}

![Kaplan-Meier analysis of the impact of TGR5 expression on disease-specific survival in patients with ampullary adeno carcinoma. (A) Disease-specific survival of all patients with ampullary adenocarcinoma who underwent surgery according to TGR5 expression level (P=0.1118). (B) Disease-specific survival of ampullary cancer patients with plasma total bilirubin concentration ≤2.45 mg/dl. TGR5 expression level was not correlated with survival (P=0.8428). (C) Disease-specific survival of ampullary cancer patients with plasma total bilirubin concentration \>2.45 mg/dl. Strong TGR5 expression predicted a better survival (P=0.0464).](OR-36-04-1997-g04){#f5-or-36-04-1997}

###### 

PrognoScan[a](#tfn1-or-36-04-1997){ref-type="table-fn"} microarray analysis of the prognostic value of *GPBAR1* in human cancer. (High *GPBAR1* gene expression predicted poor prognosis in these datasets).

  Dataset          Cancer type   End point   Cohort       Contributor   Array type                 Probe ID        No.   Cut point   Minimum P-value   Corrected P-value                                    ln (HR-high/HR-low)   COX P-value   ln (HR)   HR (95% CI)
  ---------------- ------------- ----------- ------------ ------------- -------------------------- --------------- ----- ----------- ----------------- ---------------------------------------------------- --------------------- ------------- --------- --------------------
  GSE13507         Bladder       OS          CNUH         Kim           Human-6 v2                 ILMN_1727709    165   0.61        0.000             0.014[b](#tfn2-or-36-04-1997){ref-type="table-fn"}   0.83                  0.80          −0.06     0.94 (0.57--1.54)
  GSE2658          Blood         DSS         Arkansas Z   han           HG-U133_Plus_2             1552501_a\_at   559   0.53        0.030             0.358                                                0.44                  0.62          0.08      1.08 (0.79--1.48)
  GSE7696          Brain         OS          Lausanne     Murat         HG-U133_Plus_2             1552501_a\_at   70    0.89        0.127             --                                                   0.61                  1.00          0.00      1.00 (0.18--5.57)
  GSE19615         Breast        DMFS        DF/HCC       Li            HG-U133_Plus_2             1552501_a\_at   115   0.30        0.194             --                                                   0.95                  0.77          0.18      1.20 (0.36--3.99)
  GSE12276         Breast        RFS         EMC          Bos           HG-U133_Plus_2             1552501_a\_at   204   0.43        0.051             --                                                   0.28                  0.58          0.05      1.05 (0.89--1.24)
  GSE6532-GPL570   Breast        RFS         GUYT         Loi           HG-U133_Plus_2             1552501_a\_at   87    0.83        0.232             --                                                   0.55                  0.67          −0.33     0.72 (0.16--3.31)
                                 DMFS                     Loi                                                      87    0.83        0.232             --                                                   0.55                  0.67          −0.33     0.72 (0.16--3.31)
  GSE9195          Breast        RFS         GUYT2        Loi           HG-U133_Plus_2             1552501_a\_at   77    0.16        0.102             --                                                   15.30                 0.29          1.50      4.47 (0.29--69.89)
  GSE17537         Colorectal    DFS         VMC          Smith         HG-U133_Plus_2             1552501_a\_at   55    0.49        0.047             0.472                                                1.03                  0.48          1.21      3.36 (0.12--96.71)
                                 OS                                                                                55    0.67        0.288             --                                                   0.48                  0.90          −0.18     0.83 (0.05--14.36)
  GSE3141          Lung          OS          Duke         Bild          HG-U133_Plus_2             1552501_a\_at   111   0.22        0.024             0.304                                                0.88                  0.08          0.28      1.33 (0.96--1.83)
  GSE17710         Lung          RFS         UNC          Wilkerson     Agilent-UNC-custom-4X44K   25074           56    0.68        0.159             --                                                   0.50                  0.56          0.32      1.38 (0.46--4.11)

[www.abren.net/PrognoScan/index.html](http://www.abren.net/PrognoScan/index.html).

P\<0.05 is defined as statistically significant. OS, overall survival; DSS, disease-specific survival; DMFS, disease metastasis-free survival; RFS, relapse-free survival; HR, hazard ratio; CI, confidence interval.

###### 

PrognoScan[a](#tfn3-or-36-04-1997){ref-type="table-fn"} microarray analysis of the prognostic value of *GPBAR1* in human cancer. (High *GPBAR1* gene expression predicted good prognosis in these datasets.)

  Dataset           Cancer type     End point   Cohort                                Contributor   Array type                 Probe ID                    No.   Cut point   Minimum P-value   Corrected P-value                                    ln (HR-high/HR-low)   COX P-value   ln (HR)   HR (95% CI)
  ----------------- --------------- ----------- ------------------------------------- ------------- -------------------------- --------------------------- ----- ----------- ----------------- ---------------------------------------------------- --------------------- ------------- --------- --------------------
  GSE12417-GPL570   Blood           OS          AMLCG (2004)                          Metzeler      HG-U133_Plus_2             1552501_a\_at               79    0.27        0.114             --                                                   −0.50                 0.41          −0.28     0.76 (0.39--1.47)
  GSE16581          Brain           OS          UCLA                                  Lee           HG-U133_Plus_2             1552501_a\_at               67    0.25        0.021             0.275                                                −1.44                 0.63          −0.81     0.44 (0.02--12.73)
  GSE9195           Breast          DMFS        GUYT2                                 Loi           HG-U133_Plus_2             1552501_a\_at               77    0.74        0.058             --                                                   −15.50                1.00          −0.01     0.99 (0.06--16.54)
  GSE17536          Colorectal      DFS         MCC                                   Smith         HG-U133_Plus_2             1552501_a\_at               145   0.70        0.005             0.087                                                −1.39                 0.12          −1.87     0.15 (0.01--1.62)
                                    OS                                                                                                                     177   0.85        0.035             0.389                                                −0.94                 0.25          −0.95     0.39 (0.08--1.96)
                                    DSS                                                                                                                    177   0.84        0.023             0.295                                                −1.27                 0.58          −0.52     0.60 (0.10--3.68)
  GSE14333          Colorectal      DFS         Melbourne                             Jorissen      HG-U133_Plus_2             1552501_a\_at               226   0.85        0.076             --                                                   −1.01                 0.25          −0.17     0.85 (0.64--1.13)
  GSE22138          Eye             DMFS        BRCIC                                 Laurent       HG-U133_Plus_2             1552501_a\_at               63    0.81        0.015             0.216                                                −1.60                 0.35          −6.72     0.00 (0--1599.31)
  GSE2837           Head and neck   RFS         VUMC, VAMC, UTMDACC (1992--2005)      Chung         U133_X3P                   Hs2.160954.1. S1_3p_s\_at   28    0.25        0.117             --                                                   −0.90                 0.23          −3.90     0.02 (0.00--12.57)
  GSE13213          Lung            OS          Nagoya (1995--1999, 2002--2004)       Tomida        G4112F                     A_23_P400378                117   0.31        0.107             --                                                   −0.47                 0.97          −0.01     0.99 (0.62--1.59)
  GSE31210          Lung            OS          NCCRI                                 Okayama       HG-U133_Plus_2             1552501_a\_at               204   0.87        0.121             --                                                   −1.45                 0.81          0.05      1.05 (0.70--1.58)
                                    RFS                                                                                                                    204   0.88        0.052             --                                                   −1.30                 0.48          −0.11     0.90 (0.67--1.21)
  GSE17537          Colorectal      DSS         VMC                                   Smith         HG-U133_Plus_2             1552501_a\_at               49    0.90        0.151             --                                                   −15.26                0.87          0.30      1.35 (0.04--44.67)
  GSE8894           Lung            RFS         Seoul (1995--2005)                    Lee           HG-U133_Plus_2             1552501_a\_at               138   0.26        0.002             0.048[b](#tfn4-or-36-04-1997){ref-type="table-fn"}   −0.75                 0.08          −10.60    0.00 (0.00--3.68)
  GSE17710          Lung            OS U        NC                                    Wilkerson     Agilent-UNC-custom-4X44K   25074                       56    0.21        0.267             --                                                   −0.44                 0.83          −0.11     0.89 (0.32--2.53)
  GSE9891           Ovarian         OS          AOCS, RBH, WH, NKI-AVL (1992--2006)   Tothill       HG-U133_Plus_2             1552501_a\_at               278   0.74        0.024             0.304                                                −0.50                 0.37          −0.35     0.71 (0.33--1.52)
  GSE17260          Ovarian         PFS         Niigata (1997--2008)                  Yoshihara     G4112A                     A_23_P400378                110   0.70        0.077             --                                                   −0.46                 0.99          0.00      1.00 (0.58--1.73)
                                    OS                                                                                                                     110   0.69        0.106             --                                                   −0.57                 0.56          −0.20     0.82 (0.41--1.63)
  GSE19234          Skin            OS          NYU                                   Bogunovic     HG-U133_Plus_2             1552501_a\_at               38    0.79        0.093             --                                                   −1.20                 0.31          −0.66     0.52 (0.14--1.86)

[www.abren.net/PrognoScan/index.html](http://www.abren.net/PrognoScan/index.html).

P\<0.05 is defined as statistically significant. OS, overall survival; DSS, disease-specific survival; DMFS, disease metastasis-free survival; RFS, relapse-free survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval.

###### 

Correlation of TGR5 expression with demographics and histopathological findings in patients with ampullary adenocarcinoma who underwent radical resection.

                                                                                     Expression of TGR5   P-value            
  ---------------------------------------------------------------------------------- -------------------- ------------------ -------
  Patients, n (%)                                                                    76 (77)              23 (23)            
  Gender, n (%)                                                                                                              0.481
   Female                                                                            30 (73)              11 (27)            
   Male                                                                              46 (79)              12 (21)            
  Age at surgery (years)[a](#tfn5-or-36-04-1997){ref-type="table-fn"}                65 (32--90)          68 (35--83)        0.043
  Total bilirubin (mg/dl)[a](#tfn5-or-36-04-1997){ref-type="table-fn"}               3.4 (0.2--19.6)      1.3 (0.4--16.3)    0.059
  Direct bilirubin (mg/dl)[a](#tfn5-or-36-04-1997){ref-type="table-fn"}              2.6 (0--18.0)        0.6 (0--7.3)       0.023
  Preoperative bile decompression, n (%)                                             41 (77)              12 (23%)           1.000
  CEA (ng/ml)[a](#tfn5-or-36-04-1997){ref-type="table-fn"}                           1.9 (0.1--296.3)     2.5 (0--13.0)      0.306
  CA-125 (U/ml)[a](#tfn5-or-36-04-1997){ref-type="table-fn"}                         15.4 (5.2--164.1)    11.5 (0.5--66.7)   0.099
  CA-199 (U/ml)[a](#tfn5-or-36-04-1997){ref-type="table-fn"}                         55.4 (0.3--7512.9)   44.2 (1.4--1860)   0.892
  Subtype, n (%)[b](#tfn6-or-36-04-1997){ref-type="table-fn"}                                                                0.206
   Intestinal type                                                                   37 (74)              13 (26)            
   Pancreaticoduodenal type                                                          17 (90)              2 (10)             
  Tumor type, n (%)                                                                                                          0.315
   Polypoid                                                                          40 (74)              14 (26)            
   Ulcerative                                                                        21 (87)              3 (13)             
   Mixed                                                                             15 (71)              6 (29)             
  Resection margin, n (%)                                                                                                    1.000
   Free                                                                              66 (76)              21 (24)            
   Microscopically positive                                                          8 (80)               2 (20)             
  Lymph node metastasis, n (%)[b](#tfn6-or-36-04-1997){ref-type="table-fn"}                                                  0.176
   Negative                                                                          42 (75)              14 (25)            
   Positive                                                                          30 (88)              4 (12)             
  Lymphovascular invasion, n (%)[b](#tfn6-or-36-04-1997){ref-type="table-fn"}                                                0.192
   Negative                                                                          27 (69)              12 (31)            
   Positive                                                                          34 (83)              7 (17)             
  Perineural invasion, n (%)[b](#tfn6-or-36-04-1997){ref-type="table-fn"}                                                    0.373
   Negative                                                                          28 (68)              13 (32)            
   Positive                                                                          18 (82)              4 (18)             
  Histological differentiation, n (%)[b](#tfn6-or-36-04-1997){ref-type="table-fn"}                                           0.847
   Well                                                                              31 (74)              11 (26)            
   Moderate                                                                          37 (77)              11 (23)            
   Poor                                                                              5 (83)               1 (17)             
  Pancreatic invasion, n (%)[b](#tfn6-or-36-04-1997){ref-type="table-fn"}                                                    0.149
   Negative                                                                          34 (71)              14 (29)            
   Positive                                                                          42 (84)              8 (16)             
  Tumor size (cm)[a](#tfn5-or-36-04-1997){ref-type="table-fn"}                       2.4 (0.7--8.0)       2.5 (1.0--6.0)     0.783
  Tumor stage, n (%)                                                                                                         0.063
   T1                                                                                5 (45)               6 (55)             
   T2                                                                                27 (75)              9 (25)             
   T3                                                                                29 (83)              6 (17)             
   T4                                                                                15 (88)              2 (12)             
  AJCC TNM stage, n (%)                                                                                                      0.062
   I                                                                                 26 (63)              15 (37)            
   II                                                                                34 (85)              6 (15)             
   III                                                                               15 (88)              2 (12)             
   IV                                                                                1 (100)              0 (0)              

Values are expressed as median (range).

Excluding patients without detailed records. AJCC TNM stage, American Joint Committee on Cancer tumor-node-metastases (TNM) staging system.

###### 

Correlation between disease recurrence and TGR5 expression in patients with ampullary adenocarcinoma who underwent radical resection.

                                                                                                                             Expression of TGR5   P-value    
  -------------------------------------------------------------------------------------------------------------------------- -------------------- ---------- -------
  Patients, n (%)                                                                                                            76 (77)              23 (23)    
  No recurrence, n (%)[a](#tfn7-or-36-04-1997){ref-type="table-fn"}                                                          28 (70)              12 (30)    
  Recurrence, n (%)[a](#tfn7-or-36-04-1997){ref-type="table-fn"}                                                             44 (80)              11 (20)    0.089
   Delayed recurrence, n (%)(after postoperative 12 months)                                                                  16 (70)                7 (30)   
   Early recurrence, n (%)(within postoperative 12 months)                                                                   28 (90)                3 (10)   
  Patterns of recurrence, n (%)[a](#tfn7-or-36-04-1997){ref-type="table-fn"},[b](#tfn8-or-36-04-1997){ref-type="table-fn"}                                   
   Liver metastasis, n (%)                                                                                                   19 (86)                3 (14)   0.260
   Local recurrence, n (%)                                                                                                   28 (85)                5 (15)   0.205
   Peritoneal carcinomatosis, n (%)                                                                                          12 (86)                2 (14)   0.506
   Bone metastasis, n (%)                                                                                                      6 (67)               3 (33)   0.437
   Other metastasis, n (%)[c](#tfn9-or-36-04-1997){ref-type="table-fn"}                                                      14 (82)                3 (18)   0.754

Excludes two patients who died due to surgical complications and two patients who were lost in the follow-up in our hospital.

Some patients developed more than one type of metastases.

Including brain, lung and ovary metastases.
